Oncology

Humanigen Appoints Senior Executives to Management Team

Tuesday, July 7, 2020 - 12:00pm

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.
  • All three positions report to Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.
  • He is also the founder of Black Horse Capital with decades of biotechnology investment experience.
  • We are pleased that both Dr. Chappell and Mr. Tousley, who have previously operated in interim capacities with the Company, have joined us as full-time members of the Humanigen team, stated Dr. Cameron Durrant.

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO

Tuesday, July 7, 2020 - 1:00pm

Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.

Key Points: 
  • Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.
  • The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy.
  • In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses.
  • We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program.

Stephen Squinto, Ph.D., Named Vice Chairman of bioAffinity Technologies

Tuesday, July 7, 2020 - 3:00pm

We are immensely pleased to have Dr. Squinto accept the position as Vice Chairman of the Board.

Key Points: 
  • We are immensely pleased to have Dr. Squinto accept the position as Vice Chairman of the Board.
  • He joined bioAffinity Technologies from Southwest Research Institute where he helped develop the Institutes pharmaceuticals services and bioengineering business.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
  • Research and optimization of its platform technology are conducted in bioAffinity Technologies laboratories at the University of Texas San Antonio (UTSA).

Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

Tuesday, July 7, 2020 - 12:30pm

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
  • We look forward to seeing results from the HEPANOVA trial and further exploring the potential of Tumor Treating Fields as a treatment for advanced liver cancer.
  • The safety and effectiveness of treatment with Tumor Treating Fields for liver cancer has not been established.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.

Vor Biopharma Closes $110 Million Series B Financing

Tuesday, July 7, 2020 - 12:00pm

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing.

Key Points: 
  • Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing.
  • RA Capital Management led the Series B financing, along with a diverse group of well-respected new investors including Fidelity Management & Research Company, LLC, Pagliuca Family Office, Alexandria Venture Investments, and other undisclosed investors, including additional institutional crossover investors.
  • Existing investors 5AM Ventures, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Osage University Partners, and co-founder PureTech Health participated in the financing.
  • Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies.

The Pershing Square Foundation Awards $3 Million to Innovative SARS-CoV-2 Research Projects

Tuesday, July 7, 2020 - 2:34pm

The Pershing Square Foundation (the Foundation) today announced that it has awarded $3 million to nineteen recipients at ten academic research institutions conducting research related to the SARS-CoV-2 virus.

Key Points: 
  • The Pershing Square Foundation (the Foundation) today announced that it has awarded $3 million to nineteen recipients at ten academic research institutions conducting research related to the SARS-CoV-2 virus.
  • Since 2013, the Pershing Square Sohn Cancer Research Alliance has awarded over $22 million to 39 talented scientists.
  • The Pershing Square Sohn Cancer Research Alliance was formed in 2013 through a $25 million commitment by The Pershing Square Foundation, which partnered with The Sohn Conference Foundation.
  • Annually, the Alliance awards the Pershing Square Sohn Prize to young New York based scientists who are engaged in cutting-edge cancer research.

Asuragen Announces CE Mark of AmplideX® SMA Plus Kit

Tuesday, July 7, 2020 - 8:00am

Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced CE Mark of the AmplideX SMA Plus Kit*, an in vitro diagnostic assay to aid in the diagnosis of spinal muscular atrophy (SMA) and to identify asymptomatic carriers at risk of passing along the disease to their children.

Key Points: 
  • Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced CE Mark of the AmplideX SMA Plus Kit*, an in vitro diagnostic assay to aid in the diagnosis of spinal muscular atrophy (SMA) and to identify asymptomatic carriers at risk of passing along the disease to their children.
  • SMA is a debilitating illness resulting from the deficient production of motor neurons in the central nervous system and is a leading genetic cause of infant death.
  • The AmplideX SMA Plus Kit* is the most comprehensive commercial offering available to support the diagnosis and carrier screening of SMA.
  • With the AmplideX SMA Plus Kit, laboratories how have a simple and scalable solution to deliver meaningful results in a fraction of the time compared to alternative methods.

VisionCare, Inc. Names Thomas Ruggia as New Chief Executive Officer

Monday, July 6, 2020 - 4:00pm

VisionCare, Inc. ("VisionCare), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that Thomas Ruggia has been appointed as the companys new Chief Executive Officer, effective July 6, 2020.

Key Points: 
  • VisionCare, Inc. ("VisionCare), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that Thomas Ruggia has been appointed as the companys new Chief Executive Officer, effective July 6, 2020.
  • View the full release here: https://www.businesswire.com/news/home/20200706005323/en/
    Thomas Ruggia is the new Chief Executive Officer of VisionCare, Inc. (Photo: Business Wire)
    Were thrilled to welcome Tom to VisionCare.
  • Before joining VisionCare, Mr. Ruggia spent five years at Johnson & Johnson, working at Johnson & Johnson Vision and The Janssen Pharma Co, respectively.
  • Wolfgang Tolle, who most recently served as CEO and Executive Chairman of the Board, has left VisionCare to focus on new opportunities.

Median Technologies Is Awarded the Euronext European Rising Tech Label

Monday, July 6, 2020 - 4:45pm

Median Technologies (Paris:AMLDT), The Imaging Phenomics Company (ALMDT) announced today that it has been awarded the Euronext European Rising Tech Label.

Key Points: 
  • Median Technologies (Paris:AMLDT), The Imaging Phenomics Company (ALMDT) announced today that it has been awarded the Euronext European Rising Tech Label.
  • The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mid-caps listed on Euronext markets in Amsterdam, Brussels, Dublin, Lisbon and Paris, in the Tech sector (i.e., Life Sciences, Clean Tech and Technology, Media & Telecom).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.
  • Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need.

Connectyx in Licensing Discussions for Novel Monoclonal Antibody to Treat Pediatric Glioblastoma

Monday, July 6, 2020 - 2:30pm

Boca Raton, FL, July 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc.(OTC: CTYX) (Connectyx or the Company), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it is in licensing discussions for a novel monoclonal antibody (mAB) to treat brain cancer.

Key Points: 
  • Boca Raton, FL, July 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc.(OTC: CTYX) (Connectyx or the Company), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it is in licensing discussions for a novel monoclonal antibody (mAB) to treat brain cancer.
  • Connectyx has evaluated hundreds of available pharmaceutical assets, and the management, along with the Scientific Advisory Board, have identified a novel mAB available for license to treat pediatric glioblastoma.
  • Pediatric glioblastoma (also sometimes called grade IV astrocytoma) is a malignant braintumor that is aggressive and without a defined standard therapy.
  • Connectyx is currently involved in licensing discussions with the owner of the intellectual property for an exclusive worldwide license.